Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Key catalysts approach for Orphazyme, Gemini and Immutep.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.